Sandoz Takes Aim At Ranbaxy's Generic Nexium Sales Rights
Sandoz Inc. has asked the U.S. Food and Drug Administration to find that Ranbaxy Laboratories Ltd. forfeited its six-month exclusivity over the sale of a generic version of heartburn drug Nexium,...To view the full article, register now.
Already a subscriber? Click here to view full article